February 25, 2014

DSN recently caught up with Dick Domann, VP pharmacy services for TrialCard, to talk about adherence and abandonment solutions. Capturing otherwise lost scripts is a significant opportunity for retail pharmacy, and TrialCard has a tool to help reclaim those prescriptions.

January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

August 27, 2013

How can retail pharmacy play a greater role in battling the nation's prescription drug abuse epidemic? Data. To shed light on how CVS Caremark tapped its extensive prescribing database to identify signs of potential inappropriate prescribing, CVS Caremark¹s Troy Brennan talked with DSN about the program and the ongoing efforts to combat prescription drug abuse.

August 20, 2013

A pair of pharmacists from Whitsett, N.C., were the winners of a special text-to-vote competition to highlight independent pharmacy best practices at the Cardinal Health 2013 Retail Business Conference.

August 5, 2013

Rob Hooper, national sales manager for OTC with Actavis Pharmaceutical, sat down with DSN to discuss how Actavis is preparing for the inaugural NACDS Total Store Expo. Actavis Pharmaceutical, one of the leaders in the OTC private label industry and recently acquired by Watson Pharmaceutical, plans to leverage its extensive experience within the prescription medicine business to offer best-in-class options across store brand products.

July 10, 2013

DSN had the opportunity to speak with Christian Tadrus, who has been the pharmacist at Sam’s Health Mart in the Colombia, Mo. area, since 1997. Tadrus, a member of McKesson’s Sponsored Clinical Services pharmacy network, participates in a number of adherence support programs, including the award-winning Pharmacy Intervention adherence coaching program, StudyLink patient recruitment for clinical trials program, and the RxRapid Response pharmacist survey program.

May 6, 2013

There is no substitute for the face-to-face counsel of the pharmacist in improving patient adherence — and he’s got the data to prove it. That’s the message Thrifty White president and CEO Bob Narveson had for DSNTV in part two of a frank and broad-ranging interview about the state of the industry, the role community pharmacy can play in healthcare reform and the results of an exciting new study that validates the role companies like his can play to innovate patient care, improve outcomes and lower healthcare costs.

April 12, 2013

Westport VP and general manager Paul Hemings spoke with DSN about the company's introduction of Zephrex-D, a meth-resistant pseudoephedrine product, to market. Beyond taking a bite out of the $23.5 billion methamphetamine trade, Hemings discussed the benefits of having Zephrex-D behind the pharmacy counter.

April 2, 2013

DSN caught up with Greg Bradley — president and CEO of Advantage Consumer Healthcare, a full turnkey solution center for over-the-counter medicines reaching the market — for an overview of the new marketing and sales solution company as it has recently brought to market OraSure Technologies' OraQuick Advance, a take-home HIV test kit that the Food and Drug Administration recently approved for the self-care market, and Westport Pharmaceuticals' Zephrex-D, a pseudoephedrine product with a unique point of differentiation.

July 11, 2012

DSN talked to Cardinal Health SVP independent sales Steve Lawrence about the big news from Cardinal’s 2012 Retail Business Conference, including a best practices competition for its customers, its Women in Pharmacy program and Cardinal’s joint outreach program with the Ohio State University College of Pharmacy aimed at preventing prescription drug abuse.

March 2, 2015

The FDA is expected to issue new guidance on biosimilars labeling and generic opioids before the end of year, according to a report by the Regulatory Affairs Professional Society.

February 26, 2015

Congress introdues legislation to protect FDA user fees from sequestration. 

February 26, 2015

The fixed-combination drug Avycaz was granted priority review by the Food and Drug Administration. 

February 26, 2015

Greenstone, a subsidiary of Pfizer, announced the introduction of trandolapril/verapamil hydrochloride extended-release tablets to its line of generic pharmaceutical products. 

 

February 24, 2015

The Food and Drug Administration is looking into enabling holders of abbreviated new drug applications to unilaterally update their generic drug product labels prior to any branded drug change. 

February 24, 2015

An American Academy of Neurology study found that people who exhibit a resistance to aspirin may be more likely to have more severe strokes. 

February 24, 2015

Researchers found that switching glaucoma patients to a generic prostaglandin analogue improved adherence. 

 

February 23, 2015

Combined Distributors reported that its medicine disposal product was found to exceed U.S. FDA and EPA guidelines. 

February 23, 2015

Surescripts expands reach of its electronic prior authorization solution and now reaches 250,000 prescribers.

February 20, 2015

The recently introduced Ensuring Patient Access and Effective Drug Enforcement Act of 2015 receives support from the National Association of Chain Drug Stores.

February 19, 2015

IRI and Kline & Co. establish an exclusive alliance to provide clients with a greater level of actionable insights.

February 18, 2015

Actavis on Wednesday announced that it will adopt a new corporate name — Allergan — following the anticipated, successful completion of the acquisition of Allergan.

February 18, 2015

Acura Pharmaceuticals on Monday announced the initiation of treatment in a pilot clinical study of two experimental formulations of Nexafed (pseudoephedrine HCl) extended-release tablets.

February 18, 2015

The Mentholatum Co., a division of Japan's Rohto Pharmaceutical Co., is expanding distribution of its Hada Labo Tokyo skin care in the Northeastern and Florida markets with Bed Bath & Beyond’s Harmon Face Values.